Abstract
Sarcopenia is a condition characterized by skeletal muscle mass decrease due to physiological aging or concomitant disease such as neoplasia. In cancer patients, a low lean body mass represents a negative prognostic factor for survival and development of dose-limiting chemotherapy toxicities, independent of the stage of disease. The aim of our study was to analyze the association between sarcopenia and overall survival (OS), response to therapy and toxicity in patients with metastatic colorectal cancer (mCRC) in first-line chemotherapy treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
